News Overview

Sales reported at Rs 0.01 crore

Sales rise 46.25% to Rs 5.85 crore

Investment required between Rs200 to Rs250 crore and mode of financing is internal accruals.

Sales decline 5.22% to Rs 67.90 crore

Sales rise 23.74% to Rs 774.96 crore

NRB Bearings fell 15.93% to Rs 151.50 after the companys consolidated net profit declined 46.67% to Rs 12.56 crore on 0.37% increase in net sales to Rs 257.52 crore in Q2 September 2022 over Q2 September 2021.

The key equity indices edged lower and hit fresh intraday low in early afternoon trade. The Nifty traded below the 18,200 level after hitting the days high of 18,296.40 in the early trade. Financial stocks witnessed some bit of profit booking after advancing in the past three sessions. At 12:27 IST, the barometer index, the S&P BSE Sensex, was down 106.18 points or 0.17% to […]

Issue opens on 14 November 2022

Natco Pharma announced the launch of first generic version of Pomalyst? (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCOs commercial partner Juno Pharmaceuticals. Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. Pomalyst? registered sales of USD 35.6 million in the Australian market for the year ending 31 March 2022 as per industry sales data.Powered […]

Reported sales nil